hyoscine butylbromide
Phase 2Small molecule
Boehringer Ingelheimhyoscine butylbromide is one of 36 small molecule programs targeting Constipation. It is currently in Phase 2.
2
Indications
14
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
45 competitors in Abdominal Pain
#DrugCompanyPhaseTrials
1Elavil
AstraZenecaApproved
Lopid
PfizerApproved
Niacor
AbbVieApproved
Dilaudid
RRhodes Pharmaceuticals, L.P.
Approved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Marcaine
IInnocoll
Approved
Orgovyx
Sumitomo Pharma America, Inc.Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Naropin
FFresenius Kabi Oncology Ltd.
Approved
Proair HFA
GGlaxo Dba Glaxosmithkline
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Intravenous2 trials
Effect of Intravenous Hyoscine Butylbromide Injection on Labour in High Risk Women
Completed·—·Phase 4·NCT03055390·300 enrolled
Effect of Intravenous Hyoscine Butylbromide Injection on First Stage Labour in Primigavidae
Completed·—·Phase 4·NCT02824679·200 enrolled
Labor2 trials
Effect of Hyoscine- Bromide on Duration of the First Stage of Labor
Unknown status·—·N/A·NCT06056869·60 enrolled
Abdominal pain1 trial
TED1 trial
Female1 trial
6 more indications
Acute1 trial
Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole
Completed·—·Phase 4·NCT01281501·87 enrolled
Tics1 trial
Efficacy and Safety1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for hyoscine butylbromide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company